By Mike Ward
Editor, Europe

OXFORD - British Biotech Group plc (LSE:BBG, BBIOY) entered the third phase of its post-Keith McCullagh existence when CEO Elliot Goldstein announced that the company was dropping Zacutex, the compound it was developing as a treatment for acute pancreatitis, and would be cutting another 60 employees from its payroll.